NFKB1 and myelodysplastic syndrome: Benarjee et al. suggested that the hematopoietic improvement observed in low-risk MDS patients treated with DFX may be mediated by inhibition of NF-κB transcriptional activity and production of inflammatory cytokines from resident immune cells in bone marrow [7].